TY - JOUR
T1 - Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression
T2 - an umbrella review and updated meta-analysis
AU - Tesfamicael, Kiflu G.
AU - Zhao, Lijun
AU - Fernández-Rodríguez, Rubén
AU - Adelson, David L.
AU - Musker, Michael
AU - Polasek, Thomas M.
AU - Lewis, Martin David
N1 - Publisher Copyright:
Copyright © 2024 Tesfamicael, Zhao, Fernández-Rodríguez, Adelson, Musker, Polasek and Lewis.
PY - 2024/7/11
Y1 - 2024/7/11
N2 - Aim: To determine the efficacy and safety of pharmacogenomics (PGx)-guided antidepressant prescribing in patients with depression through an umbrella review and updated meta-analysis. Methods: A comprehensive systematic search was conducted on PsycINFO, PubMed, Embase and the Cochrane databases. The pooled effect sizes of randomized controlled trials (RCTs) were expressed as mean differences for continuous data and risk ratios for noncontinuous data. Results: Patients who received PGx-guided medications were 41% to 78% more likely to achieve remission and 20% to 49% more likely to respond to antidepressants than patients receiving treatment-as-usual (TAU). Conclusion: PGx-guided antidepressant prescribing improves the treatment of depression. However, the significance and magnitude of the benefit varies widely between studies and different PGx testing panels. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022321324.
AB - Aim: To determine the efficacy and safety of pharmacogenomics (PGx)-guided antidepressant prescribing in patients with depression through an umbrella review and updated meta-analysis. Methods: A comprehensive systematic search was conducted on PsycINFO, PubMed, Embase and the Cochrane databases. The pooled effect sizes of randomized controlled trials (RCTs) were expressed as mean differences for continuous data and risk ratios for noncontinuous data. Results: Patients who received PGx-guided medications were 41% to 78% more likely to achieve remission and 20% to 49% more likely to respond to antidepressants than patients receiving treatment-as-usual (TAU). Conclusion: PGx-guided antidepressant prescribing improves the treatment of depression. However, the significance and magnitude of the benefit varies widely between studies and different PGx testing panels. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022321324.
KW - antidepressant
KW - depression
KW - genotyping panels
KW - pharmacogenomics (PGx)
KW - pharmacogenomics-guided prescribing
UR - http://www.scopus.com/inward/record.url?scp=85200216277&partnerID=8YFLogxK
U2 - 10.3389/fpsyt.2024.1276410
DO - 10.3389/fpsyt.2024.1276410
M3 - Review article
AN - SCOPUS:85200216277
SN - 1664-0640
VL - 15
JO - Frontiers in Psychiatry
JF - Frontiers in Psychiatry
M1 - 1276410
ER -